Ezkerralde-Enkarterri-Gurutzetako Erakunde Sanitario Integratua
Osakidetzako erakundea
GlaxoSmithKline (Spain)
Madrid, EspañaGlaxoSmithKline (Spain)-ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2021
-
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)
Drugs
-
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
Drugs, Vol. 81, Núm. 15, pp. 1763-1774
2016
-
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic copd spanish patients
International Journal of COPD, Vol. 11, pp. 123-132
2010
-
Antimicrobial resistance among respiratory pathogens in Spain: Latest data and changes over 11 years (1996-1997 to 2006-2007)
Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 2953-2959
2009
-
Impact of acute otitis media pathogen shifts on the clinical efficacy of several antibiotics: A therapeutic outcomes model
Journal of Chemotherapy, Vol. 21, Núm. 4, pp. 408-413
2007
-
What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 3, pp. 605-612